Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. November 2025 12:03 ET | Quelle: Raphael Pharmaceutical Inc

Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative...
07. Januar 2025 08:00 ET | Quelle: Raphael Pharmaceutical Inc

Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis

* Patients in Study Reported Lower Pain Levels, Better Sleep Quality, and Improved Wellbeing * Disease Activity Score Decreased by 19.2%, Reflecting a Shift in Disease Activity from High to Moderate *...
09. Juli 2024 08:30 ET | Quelle: Raphael Pharmaceutical Inc

Raphael Pharmaceutical Issues Letter to Shareholders

Highlights Company’s exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis, recently...